Core Viewpoint - The company has noted the approval of a generic version of its product Budesonide Enteric-Coated Capsules (耐赋康®) by the National Medical Products Administration of China, while emphasizing the protection of its original product under a valid patent until May 7, 2029 [1] Group 1 - The company holds a patent (ZL200980127272.5) for its original product in China, which is currently valid [1] - The patent information has been registered with the Chinese drug patent information registration platform [1] - According to Chinese patent law, any entity or individual must not manufacture, use, promise to sell, or import products that fall under the patent protection without the company's legal permission before the patent expires [1] Group 2 - The company reserves the right to take legal action against any infringement of the patent or violations of commitments made by generic applicants [1] - Generic applicants must adhere to their commitments if they submit a "Category 3 Declaration," promising not to market the drug before the patent expiration [1]
云顶新耀：公司原研产品耐赋康相关技术在中国受到专利保护